TY  - JOUR
T1  - Intravenous Administration of Doxycycline, Azithromycin, or their Combination for Managing Severe Scrub Typhus
AU - Suresh, M.K. AU - Nitin, R. 
JO  - Research Journal of Medical Sciences
VL  - 19
IS  - 3
SP  - 149
EP  - 153
PY  - 2025
DA  - 2001/08/19
SN  - 1815-9346
DO  - makrjms.2025.3.149.153
UR  - https://makhillpublications.co/view-article.php?doi=makrjms.2025.3.149.153
KW  - Intravenous doxycycline
KW  - incidence of organopathy
KW  - pharmacokinetic profiles
AB  - <p style="text-align:justify">To evaluate the efficacy and safety of intravenous doxycycline, azithromycin and their combination in the treatment of severe scrub typhus. A review of published literature and clinical trials, including the Interest trial and other multi centric studies, was undertaken. Data were assessed for endpoints such as 28‐day mortality, fever clearance time, incidence of organopathy, pharmacokinetic profiles, side effects and transition to oral therapy. Combination therapy showed a statistically significant reduction in organopathy compared to monotherapy, though mortality and fever clearance times were similar. Doxycycline and azithromycin exhibited favorable pharmacokinetic profiles for intravenous administration and successful transition to oral therapy. Both agents demonstrated acceptable safety profiles, with side effects such as gastrointestinal disturbances and skin reactions being the most common. Intravenous doxycycline and azithromycin, particularly in combination, offer enhanced clinical benefits in managing severe scrub typhus. Further large‐scale trials are needed to optimize treatment protocols and address long‐term concerns, such as antimicrobial resistance.</p>

ER  -